{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:49:48Z","timestamp":1789145388649,"version":"build-2803163510"},"reference-count":169,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1053\/j.seminhematol.2025.11.003","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T04:57:26Z","timestamp":1763701046000},"page":"305-318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting B-cell maturation antigen in relapsed or refractory multiple myeloma: On the verge of its prime time"],"prefix":"10.1053","volume":"62","author":[{"given":"Jun Ho","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-3548","authenticated-orcid":false,"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.11.003_bib0002","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.003_bib0003","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41588-025-02196-0","article-title":"Genomic landscape of multiple myeloma and its precursor conditions","volume":"57","author":"Alberge","year":"2025","journal-title":"Nat Genet"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_433520","article-title":"Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies","volume":"44","author":"Rees","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0005","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1177\/095952874402700129","article-title":"Remarks on the pathology of mollities ossium; with cases","volume":"27","author":"Solly","year":"1844","journal-title":"Med Chir Trans"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.003_bib0006","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1749-6632.1958.tb42675.x","article-title":"[Clinical experiences with sarcolysin in neoplastic diseases]","volume":"68","author":"Blokhin","year":"1958","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.003_bib0007","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000206984","article-title":"Identical twin marrow transplantation in multiple myeloma","volume":"68","author":"Osserman","year":"1982","journal-title":"Acta Haematol"},{"issue":"26","key":"10.1053\/j.seminhematol.2025.11.003_bib0008","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.003_bib0009","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.11.003_bib0010","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with Daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.003_bib0011","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.003_bib0012","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for Multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1053\/j.seminhematol.2025.11.003_bib0013","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.003_bib0014","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood-2011-01-332940","article-title":"Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow","volume":"118","author":"Matthes","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.003_bib0015","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0016","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J Exp Med"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.11.003_bib0017","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0018","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.11.003_bib0019","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.11.003_bib0020","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0021","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3389\/fimmu.2018.01822","article-title":"Osteoclast immunosuppressive effects in multiple myeloma: role of programmed cell death ligand 1","volume":"9","author":"Tai","year":"2018","journal-title":"Front Immunol"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0022","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.003_bib0023","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.003_bib0024","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41408-021-00505-4","article-title":"Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients","volume":"11","author":"Visram","year":"2021","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.003_bib0025","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3324\/haematol.2016.150896","article-title":"Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients","volume":"102","author":"Ghermezi","year":"2017","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0026","doi-asserted-by":"crossref","first-page":"e889","DOI":"10.1002\/jha2.889","article-title":"Increased serum B-cell maturation antigen levels evaluated with an Elecsys-based serum B-cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myeloma","volume":"6","author":"Terpos","year":"2025","journal-title":"EJHaem"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2023.1611171","article-title":"Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma","volume":"29","author":"Wiedemann","year":"2023","journal-title":"Pathol Oncol Res"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0028","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.leukres.2019.04.008","article-title":"Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells","volume":"81","author":"Chen","year":"2019","journal-title":"Leuk Res"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.11.003_bib0029","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.003_bib0030","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0031","article-title":"S194: teclistamab (TEC)\u202f+\u202fNirogacestat (NIRO) in relapsed\/refractory multiple myeloma (RRMM): the phase 1b Majestec-2 study","volume":"7","author":"Offner","year":"2023","journal-title":"Hemasphere"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0032","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1200\/JCO.2022.40.16_suppl.8019","article-title":"Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-5 study","volume":"40","author":"Lonial","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10214","key":"10.1053\/j.seminhematol.2025.11.003_bib0033","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.003_bib0034","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.003_bib0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/leu.2011.214","article-title":"Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma","volume":"26","author":"van de Donk","year":"2012","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0036","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/blood-2021-146047","article-title":"SEA-BCMA, an investigational nonfucosylated monoclonal antibody: ongoing results of a phase 1 study in patients with relapsed\/refractory multiple myeloma (SGNBCMA-001)","volume":"138","author":"Hoffman","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.003_bib0037","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1158\/1535-7163.MCT-07-0464","article-title":"Antibody targeting of B-cell maturation antigen on malignant plasma cells","volume":"6","author":"Ryan","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.003_bib0038","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1158\/2767-9764.CRC-24-0413","article-title":"Preclinical evaluation of STI-8811, a novel antibody-drug conjugate targeting BCMA for the treatment of multiple myeloma","volume":"4","author":"Springer","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"42","key":"10.1053\/j.seminhematol.2025.11.003_bib0039","doi-asserted-by":"crossref","first-page":"17852","DOI":"10.1073\/pnas.0905384106","article-title":"Immune synapse formation determines interaction forces between T cells and antigen-presenting cells measured by atomic force microscopy","volume":"106","author":"Hosseini","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183390","article-title":"Bispecific T cell engager (BiTE\u00ae) antibody constructs can mediate bystander tumor cell killing","volume":"12","author":"Ross","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.003_bib0041","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","article-title":"less-is-more\" in therapeutic antibodies: afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"10","author":"Pereira","year":"2018","journal-title":"MAbs"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.003_bib0042","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1158\/1535-7163.MCT-21-0035","article-title":"Belantamab Mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated antitumor responses In Vivo","volume":"20","author":"Montes de Oca","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.11.003_bib0043","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.003_bib0044","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41408-019-0196-6","article-title":"Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","volume":"9","author":"Trudel","year":"2019","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.003_bib0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.11.003_bib0046","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1002\/cncr.34987","article-title":"Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial","volume":"129","author":"Nooka","year":"2023","journal-title":"Cancer"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.003_bib0047","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0048","unstructured":"the FDA announced the withdrawal (revocation) of the biologics license for BLENREP. 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-accelerated-approval-belantamab-mafodotin-blmf-multiple-myeloma (accessed date 15th September, 2025)."},{"issue":"16_Supplement","key":"10.1053\/j.seminhematol.2025.11.003_bib0049","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1158\/1538-7445.AM2020-6711","article-title":"Abstract 6711: combinations of Belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and\/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma","volume":"80","author":"De Oca","year":"2020","journal-title":"Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0050","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41408-024-01155-y","article-title":"Results from Arm A of phase 1\/2 DREAMM-6 trial: Belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"14","author":"Popat","year":"2024","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.003_bib0051","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41591-023-02703-y","article-title":"Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1\/2 trial","volume":"30","author":"Trudel","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.003_bib0052","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0053","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2024.42.16_suppl.7503","article-title":"DREAMM-7 update: subgroup analyses from a phase 3 trial of Belantamab mafodotin (belamaf)\u202f+\u202fbortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Mateos","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0054","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1200\/JCO.2025.43.16_suppl.7546","volume":"43","author":"Mateos","year":"2025","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.003_bib0055","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(25)00330-4","article-title":"Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial","volume":"26","author":"Hungria","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.003_bib0056","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"Belantamab Mafodotin, Pomalidomide, and Dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0057","first-page":"PF728","article-title":"Updated results from phase 3 dreamm-8 study of Belantamab Mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed\/refractory multiple Myeloma","author":"Meletios","year":"2025","journal-title":"European Hematology Association Congress"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0058","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1182\/blood-2024-199282","article-title":"Belantamab Mafodotin plus Pomalidomide and Dexamethasone vs Pomalidomide plus Bortezomib and Dexamethasone in patients with relapsed\/refractory multiple myeloma: a subset analysis in patients who have received 1 prior line of therapy including Lenalidomide","volume":"144","author":"Beksac","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0059","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1200\/JCO.2025.43.16_suppl.7533","article-title":"DREAMM-8 study of Belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed\/refractory multiple myeloma (RRMM): a subgroup analysis in patients with high-risk cytogenetic features","volume":"43","author":"Trudel","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10245","key":"10.1053\/j.seminhematol.2025.11.003_bib0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.003_bib0061","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.003_bib0062","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0063","first-page":"PB2891","article-title":"Belantamab Mafodotin plus Bortezomib\/Dexamethasone shows similar progression-free survival to Ciltacabtagene Autoleucel in patients with relapsed \/refractory multiple myeloma: a network meta-analysis","author":"JK","year":"2025","journal-title":"European Hematology Association Congress"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.11.003_bib0064","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194978","article-title":"Management of adverse events and supportive therapy in relapsed\/refractory multiple myeloma","volume":"13","author":"Pozzi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0065","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1182\/blood-2024-209131","article-title":"Incidence and severity of hypogammaglobulinemia, and profile of infections in patients with relapsed multiple myeloma treated with Belantamab Mafodotin","volume":"144","author":"Devasia","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0066","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1182\/blood-2023-182725","article-title":"Infection risk and use of prophylaxis with anti-BCMA bispecific T cell engagers and Belantamab mafodotin for patients with relapsed and refractory multiple myeloma","volume":"142","author":"Popat","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.003_bib0067","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jop.2015.0064","article-title":"Ocular adverse events associated with antibody-drug conjugates in Human clinical trials","volume":"31","author":"Eaton","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0068","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7567","article-title":"Design of the phase 3 DREAMM-10 study: Belantamab mafodotin plus lenalidomide and dexamethasone (BRd) vs daratumumab plus lenalidomide and dexamethasone (DRd) in transplant-ineligible, newly diagnosed multiple myeloma (TI-NDMM)","volume":"43","author":"Lonial","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0069","unstructured":"FDA. July 17, 2025 Oncologic Drugs Advisory Committee (ODAC). 2025. p.https:\/\/www.youtube.com\/live\/CLhBI3UXWyg."},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.003_bib0070","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.003_bib0071","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.003_bib0072","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/bloodadvances.2024015648","article-title":"Prior exposure to Belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma","volume":"9","author":"Mohan Lal","year":"2025","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0073","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2022-157767","volume":"140","author":"Lowther","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0074","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-020-0834-9","article-title":"Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed\/refractory multiple myeloma","volume":"35","author":"Lee","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.003_bib0075","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41375-018-0278-7","article-title":"Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells","volume":"33","author":"Kinneer","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.11.003_bib0076","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1080\/10428194.2024.2373331","article-title":"Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma","volume":"65","author":"Dimopoulos","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0077","first-page":"PF749","article-title":"The anti-bcma antibody-drug conjugate Hdp-101 with a novel amanitin payload shows promising data in relapsed\/refractory multiple myeloma in a phase 1\/2a clinical trial AS it advances into cohort 7","author":"RZO","year":"2025","journal-title":"European Hematology Association Congress"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0078","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15010132","article-title":"Bispecific antibody format and the organization of immunological synapses in T cell-redirecting strategies for cancer immunotherapy","volume":"15","author":"Carrasco-Padilla","year":"2022","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.003_bib0079","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"10301","key":"10.1053\/j.seminhematol.2025.11.003_bib0080","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.003_bib0081","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0082","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0083","doi-asserted-by":"crossref","first-page":"8034","DOI":"10.1200\/JCO.2023.41.16_suppl.8034","article-title":"Durability of responses with biweekly dosing of teclistamab in patients with relapsed\/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study","volume":"41","author":"Usmani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.003_bib0084","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.003_bib0085","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0086","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-025-01149-1","article-title":"Teclistamab dosing in responders: modeling and simulation results from the MajesTEC-1 study in relapsed\/refractory multiple myeloma","author":"Guo","year":"2025","journal-title":"Target Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0087","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41408-025-01297-7","article-title":"Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium","volume":"15","author":"Pasvolsky","year":"2025","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.003_bib0088","first-page":"S409","article-title":"Teclistamab (Tec) for patients (pts) with heavily pretreated relapsed\/refractory multiple myeloma (RRMM) and renal impairment: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium","volume":"31","author":"Dima","year":"2025","journal-title":"Transplant Cellular Ther, Off Publicat Am Society Transplantat Cellular Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.003_bib0089","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1007\/s12325-023-02480-7","article-title":"Comparative efficacy of Teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma","volume":"40","author":"Moreau","year":"2023","journal-title":"Adv Ther"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.003_bib0090","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2022-0186","article-title":"Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed\/refractory multiple myeloma","volume":"12","author":"Krishnan","year":"2023","journal-title":"J Comp Eff Res"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.11.003_bib0091","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0092","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1016\/S2152-2650(24)01664-1","article-title":"MM-328 efficacy and safety of Teclistamab in patients with relapsed\/refractory multiple myeloma (RRMM) with high-risk (HR) features: a subgroup analysis from the phase 1\/2 MajesTEC-1 study","volume":"24","author":"Costa","year":"2024","journal-title":"Clin Lymph Myeloma Leuk"},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.003_bib0093","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","article-title":"Real-world analysis of teclistamab in 123 RRMM patients from Germany","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.003_bib0094","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3324\/haematol.2024.286118","article-title":"Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program","volume":"110","author":"Perrot","year":"2025","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0095","first-page":"LB4001","article-title":"Phase 2 study of Talquetamab\u202f+\u202fTeclistamab in patients with relapsed\/refractory multiple myeloma and extramedullary disease: redirectt-1","author":"Shaji Kumar","year":"2025","journal-title":"European Hematology Association Congress"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0096","year":"2024","journal-title":"CADTH reimbursement recommendation"},{"issue":"10","key":"10.1053\/j.seminhematol.2025.11.003_bib0097","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.003_bib0098","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0099","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1182\/blood-2024-208192","article-title":"MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of Elranatamab in patients with relapsed or refractory multiple myeloma","volume":"144","author":"Prince","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0100","doi-asserted-by":"crossref","first-page":"S405","DOI":"10.1016\/j.htct.2023.09.765","article-title":"Efficacy and safety of Elranatamab in patients with relapsed or refractory multiple myeloma and prior B-cell maturation antigen\u2013DIRECTED therapies: a pooled analysis from Magnetismm studies","volume":"45","author":"Nooka","year":"2023","journal-title":"Hematol, Transfus Cell Ther"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0101","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.1182\/blood-2023-182130","article-title":"Long-term efficacy and safety of Elranatamab monotherapy in the phase 2 Magnetismm-3 trial in relapsed or refractory multiple myeloma (RRMM)","volume":"142","author":"Tomasson","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0102","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13717","article-title":"Teclistamab: mechanism of action, clinical, and translational science","volume":"17","author":"Guo","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"9","key":"10.1053\/j.seminhematol.2025.11.003_bib0103","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0104","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1200\/JCO.2024.42.16_suppl.7546","article-title":"Characterization of the BCMA epitope bound by BCMA-CD3 T cell engager elranatamab","volume":"42","author":"Josic","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2147\/JBM.S507550","article-title":"Matching-adjusted indirect comparison of Elranatamab versus Teclistamab in patients with triple-class exposed\/refractory multiple myeloma: updated results","volume":"16","author":"Mol","year":"2025","journal-title":"J Blood Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.003_bib0106","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.003_bib0107","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","article-title":"A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells","volume":"5","author":"DiLillo","year":"2021","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0108","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1182\/blood-2024-208776","article-title":"Characterization of Linvoseltamab's BCMA binding epitope and efficacy against BCMA mutations in relapsed\/refractory multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0109","doi-asserted-by":"crossref","first-page":"8006","DOI":"10.1200\/JCO.2023.41.16_suppl.8006","article-title":"LINKER-MM1 study: linvoseltamab (REGN5458) in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lee","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.11.003_bib0110","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/S2152-2650(25)03517-7","article-title":"Indirect comparison of Linvoseltamab vs Teclistamab for the treatment of triple-class exposed relapsed\/refractory multiple myeloma","author":"Lee","year":"2025","journal-title":"Clin Lymph Myeloma Leuk"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0112","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1200\/JCO.2025.43.16_suppl.7531","article-title":"Indirect comparison of linvoseltamab versus elranatamab for triple-class exposed (TCE) relapsed\/refractory multiple myeloma (RRMM)","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0113","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1182\/blood-2023-179039","article-title":"Bivalent BCMA binding and low affinity CD3 T-cell engagement by Abbv-383 drives sustained activation with reduced T-cell exhaustion in preclinical models of Multiple myeloma","volume":"142","author":"Sharon","year":"2023","journal-title":"Blood"},{"issue":"31","key":"10.1053\/j.seminhematol.2025.11.003_bib0114","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-Human study of ABBV-383, a B-cell maturation antigen\u202f\u00d7\u202fCD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0115","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1200\/JCO.2024.42.16_suppl.7531","article-title":"Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Rodriguez Valdes","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0116","doi-asserted-by":"crossref","first-page":"7527","DOI":"10.1200\/JCO.2025.43.16_suppl.7527","article-title":"Long-term efficacy and safety of etentamig, a B-cell maturation antigen (BCMA) bispecific antibody in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"43","author":"Baljevic","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.003_bib0117","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.003_bib0118","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0119","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.imlet.2018.04.007","article-title":"The link between bone microenvironment and immune cells in multiple myeloma: emerging role of CD38","volume":"205","author":"Bolzoni","year":"2019","journal-title":"Immunol Lett"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.003_bib0120","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41571-024-00913-y","article-title":"Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins","volume":"21","author":"Neri","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2025.11.003_bib0121","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0122","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2025.43.16_suppl.7505","article-title":"First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): initial phase 1 results","volume":"43","author":"van de Donk","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0123","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1053\/j.seminhematol.2025.11.003_bib0124","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.11.003_bib0125","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2025.11.003_bib0126","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0127","first-page":"26","article-title":"Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2025.11.003_bib0128","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0129","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1200\/JCO.2021.39.15_suppl.8016","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results","volume":"39","author":"Anderson","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.003_bib0130","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1053\/j.seminhematol.2025.11.003_bib0131","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2025.11.003_bib0132","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.003_bib0133","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana","year":"2024","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0134","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2022-162469","article-title":"KarMMa-2 cohort 2a: efficacy and safety of Idecabtagene Vicleucel in clinical high-risk multiple myeloma patients with early relapse after frontline autologous stem cell transplantation","volume":"140","author":"Usmani","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0135","first-page":"S208","article-title":"Idecabtagene vicleucel (IDE-CEL) in patients (PTS) with clinical high-risk early relapse multiple myeloma (MM) without front-line (1L) autologous stem cell transplantation (ASCT): karmma-2 Cohort 2b","author":"AC","year":"2024","journal-title":"European Hematology Association Congress"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0136","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1182\/blood-2022-162615","article-title":"KarMMa-2 cohort 2c: efficacy and safety of Idecabtagene Vicleucel in patients with clinical high-risk multiple myeloma due to inadequate response to frontline autologous stem cell transplantation","volume":"140","author":"Dhodapkar","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0137","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.991092","article-title":"Ciltacabtagene autoleucel: the second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma","volume":"13","author":"Chekol Abebe","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0138","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","article-title":"A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma","volume":"11","author":"Zhao","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"10297","key":"10.1053\/j.seminhematol.2025.11.003_bib0139","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2025.11.003_bib0140","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2025.11.003_bib0141","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-term (\u22655-Year) remission and survival after treatment with Ciltacabtagene Autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0142","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/blood-2024-201533","article-title":"Ciltacabtagene Autoleucel (Cilta-cel) vs standard of care (SoC) in patients with lenalidomide (Len)-refractory multiple myeloma (MM) after 1-3 lines of therapy: minimal residual disease (MRD) negativity in the phase 3 Cartitude-4 trial","volume":"144","author":"Popat","year":"2024","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0143","doi-asserted-by":"crossref","first-page":"2411.2.2","DOI":"10.1182\/blood-2024-199187","article-title":"Real-world efficacy outcomes of Ciltacabtagene Autoleucel in relapsed refractory multiple myeloma: a comparative study with the Cartitude-1 trial","volume":"144","author":"Kamboj","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0144","unstructured":"Sidana S.A.-.O., Patel K.A.-.O.X., Peres L.C., et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. (1528-0020 (Electronic))."},{"issue":"2","key":"10.1053\/j.seminhematol.2025.11.003_bib0145","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.jtct.2023.12.054","volume":"30","author":"Hillengass","year":"2024","journal-title":"Off Publicat Am Society Transplantat Cellular Ther"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.003_bib0146","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0147","unstructured":"Martin T., Usmani S.Z., Schecter J.M., et al. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. (1473-4877 (Electronic))."},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0148","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70070","article-title":"Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study","volume":"9","author":"Merz","year":"2025","journal-title":"Hemasphere"},{"issue":"13","key":"10.1053\/j.seminhematol.2025.11.003_bib0149","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO-24-01730","article-title":"Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in relapsed\/refractory multiple myeloma","volume":"43","author":"Hansen","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.003_bib0150","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","article-title":"Preclinical efficacy of BCMA-directed CAR T cells incorporating a novel D domain antigen recognition domain","volume":"21","author":"Buonato","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.003_bib0151","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ymthe.2019.04.010","article-title":"Chimeric antigen receptors incorporating D domains targeting CD123 direct potent mono- and Bi-specific antitumor activity of T cells","volume":"27","author":"Qin","year":"2019","journal-title":"Mol Ther"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0152","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood-2023-189761","article-title":"Phase 1 study of CART-Ddbcma for the treatment of patients with relapsed and\/or refractory multiple myeloma: results from at least 1-year follow-up in all patients","volume":"142","author":"Frigault","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0153","first-page":"S201","article-title":"Phase 2 registrational study of anitocabtagene autoleucel for relapsed and\/or refractory multiple myeloma (RRMM): updated results from immagine-1","author":"CLF","year":"2025","journal-title":"European Hematology Association Congress"},{"issue":"6","key":"10.1053\/j.seminhematol.2025.11.003_bib0154","doi-asserted-by":"crossref","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","article-title":"CAR T-cell therapy for multiple myeloma: state of the art and prospects","volume":"8","author":"van de Donk","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0155","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood-2018-99-115319","article-title":"Clinical predictors of T cell fitness for CAR T cell manufacturing and efficacy in multiple myeloma","volume":"132","author":"Dancy","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0156","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1182\/blood-2018-99-116953","article-title":"Initial results from a phase 1 clinical study of bb21217, a next-generation anti bcma CAR T therapy","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0157","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0158","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00262-021-02959-8","article-title":"Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed\/refractory multiple myeloma: a case report and revies of the literature","volume":"71","author":"Zhao","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.003_bib0159","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/jha2.479","article-title":"CAR-T cells derived from multiple myeloma patients at diagnosis have improved cytotoxic functions compared to those produced at relapse or following daratumumab treatment","volume":"3","author":"Abecassis","year":"2022","journal-title":"EJHaem"},{"key":"10.1053\/j.seminhematol.2025.11.003_bib0160","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ebiom.2016.01.019","article-title":"Modulation of mTOR signalling triggers the formation of stem cell-like memory T cells","volume":"4","author":"Scholz","year":"2016","journal-title":"EBioMedicine"},{"issue":"21","key":"10.1053\/j.seminhematol.2025.11.003_bib0161","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1158\/1078-0432.CCR-21-0452","article-title":"Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells","volume":"27","author":"Nian","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0162","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"10.1053\/j.seminhematol.2025.11.003_bib0163","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0164","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1053\/j.seminhematol.2025.11.003_bib0165","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2025.11.003_bib0166","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2023-174841","article-title":"Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 fastcar-T cells (GC012F) As first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma","volume":"142","author":"Du","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2025.11.003_bib0167","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13045-025-01713-2","article-title":"BCMA\/GPRC5D bispecific CAR T-cell therapy for relapsed\/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial","volume":"18","author":"Yao","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2025.11.003_bib0168","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2025.11.003_bib0169","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study","volume":"8","author":"Tomasson","year":"2024","journal-title":"Hemasphere"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T14:00:45Z","timestamp":1773496845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":169,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0037196325000526"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.11.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting B-cell maturation antigen in relapsed or refractory multiple myeloma: On the verge of its prime time","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}